EE200200425A - Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid - Google Patents

Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid

Info

Publication number: EE200200425A
Authority: EE; Estonia
Prior art keywords: nicotinamide; inhibitors; useful; selective pde4; pde4 isozymes
Prior art date: 2000-01-31

Application number

EEP200200425A

Other languages

English (en)

Estonian (et)

Inventor

Marfat Anthony

James Chamber Robert

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-31

Filing date

2001-01-30

Publication date

2003-10-15

2001-01-30 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2003-10-15 Publication of EE200200425A publication Critical patent/EE200200425A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Virology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)

EEP200200425A 2000-01-31 2001-01-30 Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid EE200200425A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17928400P	2000-01-31	2000-01-31
PCT/IB2001/000124 WO2001057036A1 (en)	2000-01-31	2001-01-30	Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes

Publications (1)

Publication Number	Publication Date
EE200200425A true EE200200425A (et)	2003-10-15

Family

ID=22655931

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200425A EE200200425A (et)	2000-01-31	2001-01-30	Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid

Country Status (40)

Country	Link
US (1)	US7354941B2 (pt)
EP (1)	EP1252158B1 (pt)
JP (1)	JP3917863B2 (pt)
KR (1)	KR20020072299A (pt)
CN (1)	CN1404481A (pt)
AP (1)	AP2002002589A0 (pt)
AR (1)	AR027337A1 (pt)
AT (1)	ATE293624T1 (pt)
AU (1)	AU2700201A (pt)
BG (1)	BG106852A (pt)
BR (1)	BR0107964A (pt)
CA (1)	CA2398182C (pt)
CO (1)	CO5261634A1 (pt)
CZ (1)	CZ20022410A3 (pt)
DE (1)	DE60110205T2 (pt)
EA (1)	EA004885B1 (pt)
EE (1)	EE200200425A (pt)
ES (1)	ES2238415T3 (pt)
GE (1)	GEP20043302B (pt)
GT (1)	GT200100022A (pt)
HN (1)	HN2001000019A (pt)
HU (1)	HUP0204262A2 (pt)
IL (1)	IL150641A0 (pt)
IS (1)	IS6421A (pt)
MA (1)	MA26870A1 (pt)
MX (1)	MXPA02007419A (pt)
NO (1)	NO20023613L (pt)
NZ (1)	NZ519547A (pt)
OA (1)	OA12169A (pt)
PA (1)	PA8511201A1 (pt)
PE (1)	PE20011058A1 (pt)
PL (1)	PL357995A1 (pt)
PT (1)	PT1252158E (pt)
SK (1)	SK10142002A3 (pt)
SV (1)	SV2002000299A (pt)
TN (1)	TNSN01020A1 (pt)
TR (1)	TR200201880T2 (pt)
UY (1)	UY26569A1 (pt)
WO (1)	WO2001057036A1 (pt)
ZA (1)	ZA200206033B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE457169T1 (de) *	1998-10-15	2010-02-15	Imp Innovations Ltd	Verbindungen für die behandlung von gewichtsverlust
KR20070089761A (ko) *	2000-01-28	2007-08-31	알자 코포레이션	과포화 용액으로 포획된 화합물을 포함하는 리포좀
BR0114122A (pt)	2000-09-18	2003-07-01	Du Pont	Composto, composições fungicidas e método de controle de doenças vegetais causadas por patógenos vegetais fúngicos
US7250518B2 (en)	2001-01-31	2007-07-31	Pfizer Inc.	Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
BR0116845A (pt)	2001-01-31	2004-02-25	Pfizer Prod Inc	Derivados éter úteis como inibidores de isozimas pde4
EP1355884A1 (en)	2001-01-31	2003-10-29	Pfizer Products Inc.	Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
OA12542A (en)	2001-01-31	2006-06-05	Pfizer Prod Inc	Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
GB0118373D0 (en) *	2001-07-27	2001-09-19	Glaxo Group Ltd	Novel therapeutic method
NZ532278A (en) *	2001-09-19	2006-02-24	Altana Pharma Ag	Combination of a PDE inhibitor and an NSAID
HUP0500078A3 (en) *	2001-09-19	2010-07-28	Nycomed Gmbh	Pharmaceutical composition containing a combination of a pde inhibitor and a leukotriene receptor antagonist
IS7221A (is) *	2001-11-15	2004-04-15	Memory Pharmaceuticals Corporation	Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
ES2292988T3 (es)	2002-02-11	2008-03-16	Pfizer Inc.	Derivados de nicotinamida utiles como inhibidores de pde4.
US6756392B2 (en)	2002-02-11	2004-06-29	Pfizer Inc	Nicotinamide derivatives useful as PDE4 inhibitors
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
PL375631A1 (en) *	2002-11-27	2005-12-12	Altana Pharma Ag	Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
JPWO2004087150A1 (ja) *	2003-03-31	2006-06-29	協和醗酵工業株式会社	医薬組成物
WO2004087151A1 (ja) *	2003-03-31	2004-10-14	Kyowa Hakko Kogyo Co., Ltd.	医薬組成物
EP1616569A1 (en) *	2003-03-31	2006-01-18	Kyowa Hakko Kogyo Co., Ltd.	Medicinal composition
EP1616024A1 (en) *	2003-04-10	2006-01-18	F. Hoffmann-La Roche Ag	The use of pde4d in the screening for medicaments against atherosclerosis
WO2004104022A2 (en) *	2003-05-16	2004-12-02	The General Hospital Corporation	Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin a3), inhibitors thereof and methods of use thereof
US7153870B2 (en)	2003-07-25	2006-12-26	Pfizer Inc.	Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Compounds
GB0317516D0 (en)	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as PDE4 inhibitors
GB0317471D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Novel compounds
US7132435B2 (en)	2003-07-25	2006-11-07	Pfizer Inc.	Compounds
GB0317484D0 (en)	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as pde4 inhibitors
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
US20080194635A1 (en) *	2005-01-21	2008-08-14	Pfizer Inc.	Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide
EP1683795A1 (en) *	2005-01-21	2006-07-26	Pfizer Limited	Crystalline forms of cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl\|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0624282D0 (en) *	2006-12-05	2007-01-10	Cavalla David	Treatment of cachexia
WO2008079328A2 (en) *	2006-12-22	2008-07-03	Creighton University	Omega-5-fatty acids useful in lipoxygenase 5 inhibition and in the treatment of cancer
JP2010523695A (ja) *	2007-04-11	2010-07-15	アルコンリサーチ，リミテッド	アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
EP2196465A1 (en)	2008-12-15	2010-06-16	Almirall, S.A.	(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en)	2009-02-27	2010-09-08	Almirall, S.A.	New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
USRE46608E1 (en)	2009-09-01	2017-11-14	Catabasis Pharmaceuticals, Inc.	Fatty acid niacin conjugates and their uses
DK2473045T3 (en)	2009-09-01	2016-12-12	Catabasis Pharmaceuticals Inc	Niacin-FATTY ACID CONJUGATES AND THEIR USES
EP2380890A1 (en)	2010-04-23	2011-10-26	Almirall, S.A.	New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2386555A1 (en) *	2010-05-13	2011-11-16	Almirall, S.A.	New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2394998A1 (en)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
TWI663977B (zh) *	2015-03-17	2019-07-01	理筱龍	人蔘皂苷m1用於預防或治療矽肺病之用途
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4861891A (en) *	1988-08-31	1989-08-29	Pfizer Inc.	Antidepressant N-substituted nicotinamide compounds
TW429148B (en)	1995-10-27	2001-04-11	Pfizer	Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
TR199902432T2 (xx)	1997-04-04	2000-01-21	Prizer Products Inc.	Nikotinamid t�revleri.

2001
- 2001-01-30 HU HU0204262A patent/HUP0204262A2/hu unknown
- 2001-01-30 WO PCT/IB2001/000124 patent/WO2001057036A1/en active IP Right Grant
- 2001-01-30 AU AU27002/01A patent/AU2700201A/en not_active Abandoned
- 2001-01-30 AT AT01901333T patent/ATE293624T1/de not_active IP Right Cessation
- 2001-01-30 EA EA200200662A patent/EA004885B1/ru not_active IP Right Cessation
- 2001-01-30 PL PL01357995A patent/PL357995A1/xx not_active Application Discontinuation
- 2001-01-30 TR TR2002/01880T patent/TR200201880T2/xx unknown
- 2001-01-30 CZ CZ20022410A patent/CZ20022410A3/cs unknown
- 2001-01-30 OA OA1200200229A patent/OA12169A/en unknown
- 2001-01-30 AP APAP/P/2002/002589A patent/AP2002002589A0/en unknown
- 2001-01-30 IL IL15064101A patent/IL150641A0/xx unknown
- 2001-01-30 US US10/181,416 patent/US7354941B2/en not_active Expired - Fee Related
- 2001-01-30 CA CA002398182A patent/CA2398182C/en not_active Expired - Fee Related
- 2001-01-30 SK SK1014-2002A patent/SK10142002A3/sk unknown
- 2001-01-30 JP JP2001557868A patent/JP3917863B2/ja not_active Expired - Fee Related
- 2001-01-30 MX MXPA02007419A patent/MXPA02007419A/es active IP Right Grant
- 2001-01-30 EP EP01901333A patent/EP1252158B1/en not_active Expired - Lifetime
- 2001-01-30 EE EEP200200425A patent/EE200200425A/xx unknown
- 2001-01-30 DE DE60110205T patent/DE60110205T2/de not_active Expired - Lifetime
- 2001-01-30 GE GE4906A patent/GEP20043302B/en unknown
- 2001-01-30 NZ NZ519547A patent/NZ519547A/en unknown
- 2001-01-30 KR KR1020027009829A patent/KR20020072299A/ko not_active Application Discontinuation
- 2001-01-30 ES ES01901333T patent/ES2238415T3/es not_active Expired - Lifetime
- 2001-01-30 PT PT01901333T patent/PT1252158E/pt unknown
- 2001-01-30 CN CN01804340A patent/CN1404481A/zh active Pending
- 2001-01-30 BR BR0107964-6A patent/BR0107964A/pt not_active Application Discontinuation
- 2001-01-31 AR ARP010100436A patent/AR027337A1/es not_active Application Discontinuation
- 2001-01-31 PE PE2001000110A patent/PE20011058A1/es not_active Application Discontinuation
- 2001-01-31 SV SV2001000299A patent/SV2002000299A/es not_active Application Discontinuation
- 2001-01-31 GT GT200100022A patent/GT200100022A/es unknown
- 2001-01-31 CO CO01007017A patent/CO5261634A1/es not_active Application Discontinuation
- 2001-01-31 PA PA20018511201A patent/PA8511201A1/es unknown
- 2001-01-31 UY UY26569A patent/UY26569A1/es not_active Application Discontinuation
- 2001-01-31 TN TNTNSN01020A patent/TNSN01020A1/fr unknown
- 2001-06-30 HN HN2001000019A patent/HN2001000019A/es unknown
2002
- 2002-06-13 IS IS6421A patent/IS6421A/is unknown
- 2002-06-20 BG BG106852A patent/BG106852A/bg unknown
- 2002-07-23 MA MA26739A patent/MA26870A1/fr unknown
- 2002-07-29 ZA ZA200206033A patent/ZA200206033B/en unknown
- 2002-07-30 NO NO20023613A patent/NO20023613L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PL357995A1 (en)	2004-08-09
SV2002000299A (es)	2002-07-03
OA12169A (en)	2006-05-08
HN2001000019A (es)	2001-09-06
PA8511201A1 (es)	2002-12-11
DE60110205D1 (de)	2005-05-25
ATE293624T1 (de)	2005-05-15
IL150641A0 (en)	2003-02-12
AU2700201A (en)	2001-08-14
GT200100022A (es)	2001-10-19
AR027337A1 (es)	2003-03-26
IS6421A (is)	2002-06-13
EA004885B1 (ru)	2004-08-26
CA2398182C (en)	2007-03-13
NO20023613D0 (no)	2002-07-30
TR200201880T2 (tr)	2002-11-21
SK10142002A3 (sk)	2003-11-04
EA200200662A1 (ru)	2002-12-26
NZ519547A (en)	2004-03-26
CA2398182A1 (en)	2001-08-09
GEP20043302B (en)	2004-02-10
BG106852A (bg)	2003-02-28
BR0107964A (pt)	2002-10-29
CO5261634A1 (es)	2003-03-31
MA26870A1 (fr)	2004-12-20
US7354941B2 (en)	2008-04-08
ES2238415T3 (es)	2005-09-01
ZA200206033B (en)	2003-07-29
JP2003522176A (ja)	2003-07-22
MXPA02007419A (es)	2002-12-09
EP1252158B1 (en)	2005-04-20
UY26569A1 (es)	2001-08-27
TNSN01020A1 (fr)	2005-11-10
US20030186989A1 (en)	2003-10-02
NO20023613L (no)	2002-09-30
PT1252158E (pt)	2005-09-30
DE60110205T2 (de)	2006-01-26
JP3917863B2 (ja)	2007-05-23
PE20011058A1 (es)	2001-10-23
CZ20022410A3 (cs)	2003-08-13
WO2001057036A1 (en)	2001-08-09
AP2002002589A0 (en)	2002-09-30
CN1404481A (zh)	2003-03-19
EP1252158A1 (en)	2002-10-30
HUP0204262A2 (hu)	2003-04-28
KR20020072299A (ko)	2002-09-14

Publication	Publication Date	Title
EE200200425A (et)	2003-10-15	Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid
EE200300360A (et)	2003-12-15	PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
EE200200426A (et)	2003-12-15	PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid
ATE378049T1 (de)	2007-11-15	Nicotinamid-derivate als pde4-hemmer
EE200300361A (et)	2003-12-15	PDE4 isosüümide inhibiitoritena kasutatavad eetriderivaadid
IS8242A (is)	2006-01-19	Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar
PT1296981E (pt)	2004-12-31	Derivados substituidos da pirrolopiridinona uteis como inibidores da fosfodiesterase
GB0203193D0 (en)	2002-03-27	Nicotinamide derivatives useful as pde4 inhibitors
GB0317516D0 (en)	2003-08-27	Nicotinamide derivatives useful as PDE4 inhibitors
NO20035206D0 (no)	2003-11-24	Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
GB0317472D0 (en)	2003-08-27	Nicotinamide derivatives useful as PDE4 inhibitors
SI1252158T1 (en)	2005-10-31	Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
IS7366A (is)	2004-07-22	Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar
GT200300035A (es)	2003-09-24	Derivados de nicotinamida utiles como inhibidores de pde4
DK1252158T3 (da)	2005-08-22	Benzo-annelleret heterocyclyl-nicotinamed-derivater, der er nyttige som selektive inhibitorer af PDE4-isozymer
GB0227139D0 (en)	2002-12-24	Nicotinamide derivatives useful as pde4 inhibitors
GB0224453D0 (en)	2002-11-27	Nicotinamide derivatives useful as PDE4 inhibitors
GB0220999D0 (en)	2002-10-23	Nicotinamide derivatives useful as pde4 inhibitors
DOP2003000586A (es)	2003-08-15	Derivados de nicotinamida utiles como inhibidores de pde4

Legal Events

Date	Code	Title	Description
2003-12-15	HB1A	Correction of owner name or address